Literature DB >> 18102194

Serum neutralizing antibodies to the infecting strain of virus in poliomyelitis patients.

W M HAMMON, E C ROBERTS.   

Abstract

Entities:  

Keywords:  POLIOMYELITIS/immunity

Mesh:

Substances:

Year:  1948        PMID: 18102194     DOI: 10.3181/00379727-69-16682

Source DB:  PubMed          Journal:  Proc Soc Exp Biol Med        ISSN: 0037-9727


× No keyword cloud information.
  8 in total

1.  Development, persistence, and significance of type 2, poliomyelitis complement-fixing antibody in man.

Authors:  J CASALS; P K OLITSKY; A B SABIN
Journal:  J Exp Med       Date:  1952-07       Impact factor: 14.307

2.  Transitory appearance of type 2 neutralizing antibody in patients infected with type 1 poliomyelitis virus.

Authors:  A B SABIN
Journal:  J Exp Med       Date:  1952-07       Impact factor: 14.307

3.  Homotypic complement-fixing antibody in monkeys infected with type 2 poliomyelitis virus by the oral route.

Authors:  J CASALS; P K OLITSKY; A B SABIN
Journal:  J Exp Med       Date:  1952-07       Impact factor: 14.307

4.  Relationship between serum antibodies and subclinical infections with poliomyelitis virus.

Authors:  G C BROWN; J D AINSLIE
Journal:  J Exp Med       Date:  1951-03       Impact factor: 14.307

5.  Antibody response of patients with poliomyelitis to virus recovered from their own alimentary tract.

Authors:  A J STEIGMAN; A B SABIN
Journal:  J Exp Med       Date:  1949-10       Impact factor: 14.307

6.  Viremia in human poliomyelitis.

Authors:  D M HORSTMANN; R W McCOLLUM; A D MASCOLA
Journal:  J Exp Med       Date:  1954-04-01       Impact factor: 14.307

7.  Poliomyelitis in chimpanzees; studies in homologous and heterologous immunity following inapparent infection.

Authors:  D M HORSTMANN; J L MELNICK
Journal:  J Exp Med       Date:  1950-06-01       Impact factor: 14.307

8.  Levels of homotypic neutralizing antibody in human poliomyelitis three years after infection.

Authors:  J WINSSER; A B SABIN
Journal:  J Exp Med       Date:  1952-11       Impact factor: 14.307

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.